# A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

Study · id `cardio:ct-nct01157455` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01157455](<https://clinicaltrials.gov/study/NCT01157455>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01157455

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1900 participants.

## Technical summary

Registry record NCT01157455. Allocation not applicable; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1900 participants (planned count; ClinicalTrials.gov record NCT01157455, source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01157455, source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)
- Primary completion: 2012-03 (anticipated) (ClinicalTrials.gov record NCT01157455, source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)
- Completion: 2013-06 (anticipated) (ClinicalTrials.gov record NCT01157455, source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01157455, source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01157455-2010-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
- Acronym: SEEDS
- Condition: Coronary Artery Diseases
- Intervention (Procedure): Everolimus Drug Eluting Stent
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Heparin or Bivalirudin
- Lead sponsor: CCRF Consulting Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)

## Provenance

Content hash: c3494bf8ab7a65b8b479d56d29200adcd5863fbe69b1969ea1623349b6684775
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
